VitriVax Raises $17.25M Series B to Advance Thermostable Vaccine Technology

Deal Summary

VitriVax, a Boulder-based vaccine formulation technology company, raised $17.25M in a Series B round co-led by Adjuvant Capital and RA Capital Management to fund development and commercialization of its ALTA® thermostable antigen and adjuvant technology. Proceeds will support continued product development and commercialization efforts.